Education
About Us
Working with TipRanks
Follow Us
Shanghai Henlius Biotech, Inc. Class H (HK:2696)
:2696
RESEARCH TOOLSreports
2696 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$15.20 - HK$49.95
Previous CloseN/A
Volume849.10K
Average Volume (3M)1.03M
Market Cap
HK$24.78B
Enterprise ValueHK$20.78B
Total Cash (Recent Filing)HK$772.96M
Total Debt (Recent Filing)¥3.65B
Price to Earnings (P/E)29.5
Beta0.60
Next Earnings
Aug 14, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.64
Shares Outstanding163,428,540
10 Day Avg. Volume1,233,525
30 Day Avg. Volume1,026,320
Financial Highlights & Ratios
PEG Ratio1.98
Price to Book (P/B)5.91
Price to Sales (P/S)0.00
P/FCF Ratio121.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Shanghai Henlius Biotech, Inc. Class H News
PremiumCompany Announcements
Shanghai Henlius Biotech Gains Approval for H Share Full Circulation
PremiumCompany Announcements
Shanghai Henlius Initiates Clinical Study for Ipilimumab BiosimilarPremiumCompany Announcements
Shanghai Henlius Biotech Joins MSCI Global Small Cap Indexes
PremiumCompany Announcements
Shanghai Henlius Biotech Approves Key Resolutions at 2025 AGM
PremiumCompany Announcements
Shanghai Henlius Partners with Sandoz for Global Commercialization of HLX13
PremiumCompany Announcements
Shanghai Henlius Biotech Advances Phase 3 Trial for Cancer Treatment
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.04%
Mutual Funds
― Other Institutional Investors
99.86% Public Companies and
Individual Investors
2696 FAQ
What was Shanghai Henlius Biotech, Inc. Class H’s price range in the past 12 months?
Shanghai Henlius Biotech, Inc. Class H lowest stock price was HK$15.20 and its highest was HK$49.95 in the past 12 months.
What is Shanghai Henlius Biotech, Inc. Class H’s market cap?
Shanghai Henlius Biotech, Inc. Class H’s market cap is HK$24.78B.
When is Shanghai Henlius Biotech, Inc. Class H’s upcoming earnings report date?
Shanghai Henlius Biotech, Inc. Class H’s upcoming earnings report date is Aug 14, 2025 which is in 65 days.
How were Shanghai Henlius Biotech, Inc. Class H’s earnings last quarter?
Shanghai Henlius Biotech, Inc. Class H released its earnings results on Mar 24, 2025. The company reported HK$0.867 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.867.
Is Shanghai Henlius Biotech, Inc. Class H overvalued?
According to Wall Street analysts Shanghai Henlius Biotech, Inc. Class H’s price is currently Overvalued.
Does Shanghai Henlius Biotech, Inc. Class H pay dividends?
Shanghai Henlius Biotech, Inc. Class H does not currently pay dividends.
What is Shanghai Henlius Biotech, Inc. Class H’s EPS estimate?
Shanghai Henlius Biotech, Inc. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shanghai Henlius Biotech, Inc. Class H have?
Shanghai Henlius Biotech, Inc. Class H has 163,428,540 shares outstanding.
What happened to Shanghai Henlius Biotech, Inc. Class H’s price movement after its last earnings report?
Shanghai Henlius Biotech, Inc. Class H reported an EPS of HK$0.867 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 3.607%.
Which hedge fund is a major shareholder of Shanghai Henlius Biotech, Inc. Class H?
Currently, no hedge funds are holding shares in HK:2696
Shanghai Henlius Biotech, Inc. Class H Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
142.03%
12-Months-Change
Fundamentals
Return on Equity
31.65%
Trailing 12-Months
Asset Growth
3.43%
Trailing 12-Months
Company Description
Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. Class H (2696) is a leading biopharmaceutical company specializing in the research, development, manufacture, and commercialization of monoclonal antibody (mAb) drugs and other biologics. Operating in the healthcare sector, Henlius is committed to providing high-quality, affordable biologics for patients worldwide. The company's diversified portfolio includes biosimilars, innovative biologics, and immuno-oncology drugs, with a focus on oncology, autoimmunity, and ophthalmology.
2696 Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Viva Biotech Holdings
―
3SBio
―
Sino Biopharmaceutical
―
Wuxi Biologics (Cayman)
―
CSPC Pharmaceutical Group
―